Trihexyphenidyl has been found to be an effective treatment for dystonic movement disorders, improving gross motor function in patients with axial and torsional dystonia, tremors, and myoclonus, In this report, improv...
详细信息
Trihexyphenidyl has been found to be an effective treatment for dystonic movement disorders, improving gross motor function in patients with axial and torsional dystonia, tremors, and myoclonus, In this report, improvements in fine motor control, language, and oral motor skills are described with trihexyphenidyl in an 8-year-old female who developed dystonia after spontaneous bilateral putamenal hemorrhages. No adverse side effects occurred. The mechanism of action of trihexyphenidyl is believed to be in the basal ganglia where it inhibits muscarinic cholinergic receptors and increases the turnover of dopamine. (C) 1999 by Elsevier Science Inc. All rights reserved.
Tuberculosis is a major cause of illness and death worldwide. The epidemic of the acquired immunodeficiency syndrome and the increased number of other immuno compromised hosts have led to a remarkable increase in Myco...
详细信息
Tuberculosis is a major cause of illness and death worldwide. The epidemic of the acquired immunodeficiency syndrome and the increased number of other immuno compromised hosts have led to a remarkable increase in Mycobacterium avium-intracellulare complex infections. Adequate diagnostic, prevention, and treatment measures are available;however, resources for implementing these measures are limited. Processes for using these limited resources are not always well organized. This review of prevention and treatment of tuberculosis, including the six major recommendations from the Centers for Disease Control and Prevention, treatment of certain other mycobacterial infections, and information on some antimycobacterial agents, such as isoniazid, rifampin, rifabutin, pyrazinamide, and ethambutol, was written mainly for primary-care providers.
Ventricular tachycardia, which causes hemodynamic instability, and ventricular fibrillation do not occur frequently in any hospital. However, they usually occur in patients who have severe underlying cardiovascular di...
详细信息
Ventricular tachycardia, which causes hemodynamic instability, and ventricular fibrillation do not occur frequently in any hospital. However, they usually occur in patients who have severe underlying cardiovascular disease such as myocardial ischemia/infarction or congestive heart failure, and they are associated with high mortality. Most of those deaths are due to an intractable arrhythmia, not suppressible with even the most potent antiarrhythmic drugs. Fortunately, during the last few years, our ability to suppress highly lethal ventricular arrhythmia has been enhanced by the approval of intravenous amiodarone. When used in appropriate patient populations, intravenous amiodarone has been successful in suppressing the most malignant arrhythmia, thus permitting aggressive and successful treatment of severe underlying cardiac conditions. This article reviews data on the use of parenteral antiarrhythmic drugs for the control of ventricular arrhythmia in patients in hospital, and will attempt to provide some guidance as to how these antiarrhythmic drugs may be used in specific patient populations to maximize their efficacy and safety. We will also make recommendations on the sequence of therapy for specific arrhythmias to optimize the chances of patient survival. (C)1999 by Excerpta Medica, Inc.
作者：
Meredith, PAUniv Glasgow
Western Infirm Gardiner Inst Dept Med & Therapeut Glasgow G11 6NT Lanark Scotland
An optimal antihypertensive drug produces superior blood pressure-lowering effects at established dosages, with an acceptably low incidence of side effects, and at a dosage interval that is convenient for patients (id...
详细信息
An optimal antihypertensive drug produces superior blood pressure-lowering effects at established dosages, with an acceptably low incidence of side effects, and at a dosage interval that is convenient for patients (ideally, once daily). The angiotensin II receptor antagonist, telmisartan, meets these criteria. At doses of greater than or equal to 40 mg, this once-daily drug produces a statistically significant reduction in blood pressure. Ambulatory blood pressure monitoring (ABPM) and high trough-peak ratios attest to the smooth, consistent blood pressure-lowering effect of telmisartan at 40- and 80-mg dosages. Telmisartan also demonstrates a statistically superior antihypertensive effect toward the end of the dosing interval compared with amlodipine and losartan, and it has a side-effect profile comparable to that of placebo. In summary, the evidence suggests that telmisartan at dosages of 40 and 80 mg once daily satisfies the 3 criteria of an ideal antihypertensive agent, producing an effective and sustained response with placebo-like tolerability. (C) 1999 by Excerpta Medica, Inc.
Epirubicin in a breast cancer patient with Gilbert's syndrome: Apparent lack of major pharmacokinetic alterations M. Riggi Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Riggi I...
详细信息
Epirubicin in a breast cancer patient with Gilbert's syndrome: Apparent lack of major pharmacokinetic alterations M. Riggi Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Riggi I. Poggesi Search for other works by this author on: Oxford Academic PubMed Google Scholar I. Poggesi M. B. Regazzi Search for other works by this author on: Oxford Academic PubMed Google Scholar M. B. Regazzi S. Grasso Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Grasso A. Fittipaldo Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Fittipaldo R. J. Seematter Search for other works by this author on: Oxford Academic PubMed Google Scholar R. J. Seematter Annals of Oncology, Volume 10, Issue 3, 1 March 1999, Pages 360–361, https://***/10.1023/A:1008316323854 Published: 01 March 1999
暂无评论